VIP: The Neuropeptide That Talks to Your Immune System 

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is VIP?

Most people think of the nervous system and the immune system as separate. One handles sensation and movement; the other fights infection. But the body does not draw that line so cleanly. The nervous system and the immune system are in constant communication, and one of the most important messengers in that conversation is a naturally occurring peptide called vasoactive intestinal peptide, or VIP. 

VIP is a 28-amino acid neuropeptide that the body produces in the gut, the lungs, the brain, and the immune system itself. It was first discovered in the 1970s and named for its ability to widen blood vessels. But that turned out to be only a small part of what it does. Over the following decades, researchers found that VIP plays a broad role in regulating inflammation, immune cell behavior, and the balance between the immune responses that attack threats and the ones that prevent the immune system from attacking the body itself.¹ 

As a synthetic peptide, VIP is an investigational compound. It is not FDA-approved for any indication, though it has been studied in early clinical trials for conditions including rheumatoid arthritis and inflammatory bowel disease. The research is still in early stages, but the biology behind VIP is among the most well-characterized of any anti-inflammatory neuropeptide. 

Fast Facts

How Does VIP Work?

VIP works by binding to two receptors found on the surface of immune cells: VPAC1 and VPAC2. These receptors are present on T cells (the immune cells that direct the immune response), macrophages (the cells that consume and destroy pathogens), and dendritic cells (the cells that decide whether to launch an attack or stand down). When VIP binds to these receptors, it triggers a chain of events inside the cell that shifts the immune response in a specific direction. 

1. From Attack Mode to Tolerance 

The immune system has two broad modes. One is inflammatory, where it produces proteins called cytokines that recruit more immune cells and amplify the attack on a threat. The other is tolerogenic, where it produces signals that calm the response and prevent the immune system from attacking healthy tissue. In autoimmune diseases, the inflammatory mode is stuck in the on position. 

VIP pushes the immune system toward the tolerogenic mode. It reduces the production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, while increasing the production of anti-inflammatory signals including IL-10. It also promotes the development of a type of immune cell called regulatory T cells, which act as a brake on the immune response.¹ In animal models of autoimmune disease, this shift has been associated with reduced tissue damage and symptom severity. 

2. A Neuropeptide With Broad Reach 

What makes VIP unusual among anti-inflammatory peptides is how widely it is distributed in the body. It is produced by nerve fibers that run directly into lymph nodes, the spleen, and the gut wall, meaning the nervous system can release VIP directly into immune tissue. It is also produced by immune cells themselves, which can release it in response to inflammatory signals. This gives VIP a dual role: it is both a messenger from the nervous system to the immune system and a self-regulating signal within the immune system.² VIP has also been described as having pleiotropic immune functions, meaning it acts across many different immune cell types and pathways simultaneously.³ 

What Does the Research Say?

VIP has a more substantial research base than many investigational peptides, including both preclinical work and early human trials. The human data is limited in scale, but it is more than most compounds at this stage have. PeptideMatch.io presents this data so our community can understand what the science currently shows and where the research stands. 

The most significant limitation in VIP research is its very short half-life. In the bloodstream, VIP is broken down by enzymes in approximately 2 minutes, which makes it difficult to deliver therapeutically. Much of the current research effort is focused on developing VIP analogues, which are modified versions of VIP that resist breakdown and stay active longer. Some of these analogues have entered early clinical trials, but results are not yet available at scale. 

Hair Follicle Vitality

One of the most significant areas of study involves AHK-Cu’s effect on human hair follicle cells. In laboratory settings, the peptide was associated with a reduction in programmed cell death (apoptosis) within the follicle, suggesting it may help extend the active growth phase of hair.

Scalp Skin Integrity

Beyond the hair itself, research has focused on the quality of the scalp skin. Studies have shown that topical application of AHK-Cu can lead to a measurable increase in skin thickness and elasticity, creating a healthier foundation for hair growth.⁶

VIP and Inflammation

The conditions that have attracted the most research attention for VIP are those where the immune system is chronically overactive: rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and lupus. In all of these conditions, the immune system is attacking the body’s own tissue, and the inflammatory cytokines that VIP suppresses are central to the damage being done.

The research points to several areas of interest for VIP as an anti-inflammatory neuropeptide:

• Cytokine suppression: In preclinical models, VIP was associated with significant reductions in TNF-alpha, IL-6, and IL-12, the same cytokines that are targeted by some of the most widely used biologic drugs for autoimmune disease.¹
• Regulatory T cell promotion: VIP was associated with increased numbers of regulatory T cells, the immune cells that act as a brake on the immune response. Reduced regulatory T cell activity is a feature of many autoimmune conditions.²
• Gut inflammation: In the Crohn’s disease model, VIP was associated with reduced intestinal inflammation and improved tissue integrity, suggesting potential relevance for inflammatory bowel disease.⁴

It is important to note that the human clinical trial data for VIP is limited. The Phase 1 and Phase 2 trials that have been conducted are small and have not yet produced the kind of large-scale, randomized controlled trial data that would be needed to draw firm conclusions about efficacy in people. The preclinical data is compelling, but the translation from animal models to human outcomes in autoimmune disease research is historically difficult.

Safety Profile

VIP is a naturally occurring peptide that the body produces itself, which gives it a different starting point than fully synthetic compounds. The early clinical trials have not reported serious adverse events at the doses studied. The most commonly noted effects in early human studies were mild and temporary, including flushing and low blood pressure, which are consistent with VIP’s known ability to widen blood vessels.¹ A Phase 2 clinical trial evaluating inhaled VIP for pulmonary hypertension reported improvements in exercise capacity and pulmonary vascular resistance, providing some of the earliest human evidence of VIP’s therapeutic potential.⁵

Important Considerations

Regulatory Status

Not approved by the FDA or equivalent bodies for standard clinical use

Research Gaps

Long-term safety and human dosing data remain limited

Medical Oversight

Always work with a licensed healthcare provider before considering peptide therapy.

Scientific References

1. Martinez C, Juarranz Y, Gutiérrez-Canas I, et al. A clinical approach for the use of VIP axis in inflammatory and autoimmune diseases. Frontiers in Endocrinology. 2020;11:1-19.
2. Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiologica. 2015;213(2):442-452.
3. Abad C, Juarranz Y, Martínez C, et al. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Gastroenterology. 2003;124(5):1321-1340.
4. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25-39.
5. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation. 2003;111(9):1339-1346.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io.

For licensing or reprint inquiries, please contact content@peptidematch.io.